Description: Levodopa (L-DOPA) is the L-isomer of DOPA and the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline), it is used to treat Parkinson's symptoms. Levodopa is a chemical that is made and used as part of the normal biology of humans, some animals and plants. Some animals and humans make it via biosynthesis from the amino acid L-tyrosine. Furthermore, L-DOPA itself mediates neurotrophic factor release by the brain and CNS.
References: Neuroreport. 1993 Apr;4(4):438-40; Eur J Neurosci. 2003 Sep;18(6):1607-14.
Related CAS #: 1421-65-4 (HCl) 59-92-7 (free base)
Chemical Name: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
InChi Key: WTDRDQBEARUVNC-LURJTMIESA-N
InChi Code: InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1
SMILES Code: O=C(O)[[email protected]@H](N)CC1=CC=C(O)C(O)=C1
Levodopa, 3,4-Dihydroxyphenylalanin; L-DOPA, Dopar, Sinemet, Pharmacopa, Atamet, Stalevo, Madopar, Prolopa
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
In vitro activity: Levodopa produces at 25-200 μM concentrations a dose-dependent reduction of 3H-DA uptake in foetal rat midbrain cultures. Levodopa results in a decrease in the number of viable cells and tyrosine hydroxylase (TH) positive neurones, plus disruption of the overall neuritic network. Levodopa induces dyskinesia in the absence of dopamine by excessive inhibition of neurons of the putamen-globus pallidus (GPe) projection and subsequent disinhibition of the globus pallidus (GPe). Levodopa results in a decrease in cytochrome oxidase messenger RNA expression in the globus pallidus (GPi).
Neuroreport. 1993 Apr;4(4):438-40; Eur J Neurosci. 2003 Sep;18(6):1607-14.
Purity ≥98%
COA
MSDS